MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes

NEW YORK, Sept. 2, 2021 /CNW/ — MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the “Company”), a leading biotech…

MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders

NEW YORK, Aug. 24, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the…

MindMed Joins Critical Path Institute’s Patient-Reported Outcome Consortium

NEW YORK, Aug. 17, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the…

MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline

NEW YORK, Aug. 12, 2021 /CNW/ — MindMed (Nasdaq: MNMD), (NEO: MMED), (DE: MMQ), a leading biotech company developing…

MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board

NEW YORK, Aug. 10, 2021 /CNW/ — MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company…

MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology

NEW YORK, Aug. 3, 2021 /CNW/ — MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company…

MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT

NEW YORK, July 28, 2021 /CNW/ — MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing…

MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company

NEW YORK, July 8, 2021 /CNW/ — MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing…

MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board

NEW YORK, June 23, 2021 /CNW/ — MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ) (the “Company”), a leading biotech…

MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board

NEW YORK, June 17, 2021 /CNW/ — MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the “Company”), a leading…

MindMed Announces Chief Executive Officer Transition

NEW YORK, June 9, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”),…

MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing

NEW YORK, May 26, 2021 /CNW/ — MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine…